Skip to main content

Table 2 Correlation of genetic alteration according to the various criteria

From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer

Characteristics

Amplification

GCN gain

ASCO/CAP criteria

Negative

Positive

P

CN <4

4≤ CN

P

Negative

Equivocal

Positive

P

EGFR

 Location

  

1.000

  

0.803

   

0.419

  Right colon

91 (97.8%)

2 (2.2%)

 

89 (95.7%)

4 (4.3%)

 

89 (95.7%)

2 (2.2%)

2 (2.2%)

 

  Left colon

124 (97.6%)

3 (2.4%)

 

123 (96.9%)

4 (3.1%)

 

123 (96.9%)

0 (0%)

4 (3.1%)

 

  Rectum

111 (97.4%)

3 (2.6%)

 

111 (97.4%)

3 (2.6%)

 

111 (97.4%)

0 (0%)

3 (2.6%)

 

 pTNM stage

  

1.000

  

0.429

   

0.045

  I–III

266 (97.4%)

7 (2.6%)

 

265 (97.1%)

8 (2.9%)

 

265 (97.1%)

0 (0%)

8 (2.9%)

 

  IV

60 (98.4%)

1 (1.6%)

 

58 (95.1%)

3 (4.9%)

 

58 (95.1%)

2 (3.3%)

1 (1.6%)

 

 MSI status (n = 323)

  

1.000

  

0.609

   

1.000

  MSS/MSI-L

288 (97.3%)

8 (2.7%)

 

285 (96.3%)

11 (3.7%)

 

285 (96.3%)

2 (0.7%)

9 (3.0%)

 

  MSI-H

27 (100%)

0 (0%)

 

27 (100%)

0 (0%)

 

27 (100%)

0 (0%)

0 (0%)

 

HER2

 Location

  

0.011

  

0.073

   

0.015

  Right colon

90 (96.8%)

3 (3.2%)

 

89 (95.7%)

4 (4.3%)

 

89 (95.7%)

1 (1.1%)

3 (3.2%)

 

  Left colon

123 (96.9%)

4 (3.1%)

 

117 (92.1%)

10 (7.9%)

 

116 (91.3%)

7 (5.5%)

4 (3.1%)

 

  Rectum

101 (88.6%)

13 (11.4%)

 

99 (86.8%)

15 (13.2%)

 

99 (86.8%)

2 (1.8%)

13 (11.4%)

 

 pTNM stage

  

1.000

  

0.248

   

0.422

  I–III

256 (93.8%)

17 (6.2%)

 

247 (90.5%)

26 (9.5%)

 

246 (90.1%)

10 (3.7%)

17 (6.2%)

 

  IV

58 (95.1%)

3 (4.9%)

 

58 (95.1%)

3 (4.9%)

 

58 (95.1%)

0 (0%)

3 (4.9%)

 

MSI status (n = 323)

  

1.000

  

0.491

   

1.000

 MSS/MSI-L

278 (93.9%)

18 (6.1%)

 

269 (90.9%)

27 (9.1%)

 

268 (90.5%)

10 (3.4%)

18 (6.1%)

 

  MSI-H

26 (96.3%)

1 (3.7%)

 

26 (96.3%)

1 (3.7%)

 

26 (96.3%)

0 (0%)

1 (3.7%)

 

c-MYC

 Location

  

0.056

  

0.042

   

0.083

  Right colon

88 (94.6%)

5 (5.4%)

 

82 (88.2%)

11 (11.8%)

 

82 (88.2%)

6 (6.5%)

5 (5.4%)

 

  Left colon

110 (86.6%)

17 (13.4%)

 

96 (75.6%)

31 (24.4%)

 

96 (75.6%)

13 (10.2%)

18 (14.2%)

 

  Rectum

107 (93.9%)

7 (6.1%)

 

96 (84.2%)

18 (15.8%)

 

96 (84.2%)

11 (9.6%)

7 (6.1%)

 

 pTNM stage

  

0.723

  

0.136

   

0.199

  I–III

250 (91.6%)

23 (8.4%)

 

228 (83.5%)

45 (16.5%)

 

228 (83.5%)

21 (7.7%)

24 (8.8%)

 

  IV

55 (90.2%)

6 (9.8%)

 

46 (75.4%)

15 (24.6%)

 

46 (75.4%)

9 (14.8%)

6 (9.8%)

 

 MSI status (n = 323)

  

0.491

  

0.061

   

0.155

  MSS/MSI-L

269 (90.9%)

27 (9.1%)

 

240 (81.1%)

56 (18.9%)

 

240 (81.1%)

28 (9.5%)

28 (9.5%)

 

  MSI-H

26 (96.3%)

1 (3.7%)

 

26 (96.3%)

1 (3.7%)

 

26 (96.3%)

0 (0%)

1 (3.7%)

 

MET

 Location

  

0.427

  

0.602

   

0.536

  Right colon

87 (93.5%)

6 (6.5%)

 

77 (82.8%)

16 (17.2%)

 

75 (80.6%)

10 (10.8%)

8 (8.6%)

 

  Left colon

122 (96.1%)

5 (3.9%)

 

109 (85.8%)

18 (14.2%)

 

106 (83.5%)

15 (11.8%)

6 (4.7%)

 

  Rectum

111 (97.4%)

3 (2.6%)

 

100 (87.7%

14 (12.3%)

 

99 (86.8%)

11 (9.6%)

4 (3.5%)

 

 pTNM stage

  

1.000

  

0.003

   

0.020

  I–III

261 (95.6%)

12 (4.4%)

 

241 (88.3%)

32 (11.7%)

 

235 (86.1%)

23 (8.4%)

15 (5.5%)

 

  IV

59 (96.7%)

2 (3.3%)

 

45 (73.8%)

16 (26.2%)

 

45 (73.8%)

13 (21.3%)

3 (4.9%)

 

 MSI status (n = 323)

  

0.609

  

0.147

   

0.298

  MSS/MSI-L

284 (95.9%)

12 (4.1%)

 

252 (85.1%)

44 (14.9%)

 

247 (83.4%)

33 (11.1%)

16 (5.4%)

 

  MSI-H

27 (100%)

0 (0%)

 

26 (96.3%)

1 (3.7%)

 

26 (96.3%)

1 (3.7%)

0 (0%)

 
  1. MSI microsatellite instability, MSS microsatellite instability stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, GCN gene copy number, CN copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists